Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients

Journal of Immunological Methods

Volumn 348, Issue 1-2, 2009, Pages 9-17

  Gannon, Philippe O ^a   Poisson, Alexis O ^a   Delvoye, Nathalie ^a   Lapointe, Réjean ^a,b   Mes Masson, Anne Marie ^a,b   Saad, Fred ^a,c  

^a NOTRE DAME HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Androgen deprivation therapy; Computer assisted quantification; Immunohistochemistry; Macrophages; NK cells; Prostate cancer; Tumor infiltrating lymphocytes

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYPROTERONE; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMISTRY; CANCER PATIENT; CANCER RECURRENCE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL INFILTRATION; CELL TYPE; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE COURSE; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR GROWTH;

EID: 68749087029     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.06.004     Document Type: Article

References (36)

1. Civantos F., Soloway M.S., and Pinto J.E. Histopathological effects of androgen deprivation in prostatic cancer. Semin. Urol. Oncol. 14 (1996) 22
2. Diallo J.S., Aldejmah A., Mouhim A.F., Fahmy M.A., Koumakpayi I.H., Sircar K., Begin L.R., Mes-Masson A.M., and Saad F. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU Int. 101 (2008) 1302
3. Diallo J.S., Aldejmah A., Mouhim A.F., Peant B., Fahmy M.A., Koumakpayi I.H., Sircar K., Begin L.R., Mes-Masson A.M., and Saad F. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin. Cancer Res. 13 (2007) 7044
4. Drake C.G., Doody A.D., Mihalyo M.A., Huang C.T., Kelleher E., Ravi S., Hipkiss E.L., Flies D.B., Kennedy E.P., Long M., McGary P.W., Coryell L., Nelson W.G., Pardoll D.M., and Adler A.J. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cells 7 (2005) 239
5. Fox S.B., Launchbury R., Bates G.J., Han C., Shaida N., Malone P.R., Harris A.L., and Banham A.H. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. Prostate 67 (2007) 623
6. Fradet V., Lessard L., Begin L.R., Karakiewicz P., Masson A.M., and Saad F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin. Cancer Res. 10 (2004) 8460
7. Gannon P.O., Alam Fahmy M., Begin L.R., Djoukhadjian A., Filali-Mouhim A., Lapointe R., Mes-Masson A.M., and Saad F. Presence of prostate cancer metastasis correlates with lower lymph node reactivity. Prostate 66 (2006) 1710
8. Grossmann M.E., Huang H., and Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 93 (2001) 1687
9. Guinan P., Didomenico D., Brown J., Shaw M., Sharifi R., Ray V., Shott S., and Rubenstein M. The effect of androgen deprivation on malignant and benign prostate tissue. Med Oncol 14 (1997) 145
10. Haverkamp J., Charbonneau B., and Ratliff T.L. Prostate inflammation and its potential impact on prostate cancer: a current review. J. Cell. Biochem. 103 (2008) 1344
11. Irani J., Goujon J.M., Ragni E., Peyrat L., Hubert J., Saint F., and Mottet N. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 54 (1999) 467
12. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71
13. Karja V., Aaltomaa S., Lipponen P., Isotalo T., Talja M., and Mokka R. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res. 25 (2005) 4435
14. Koumakpayi I.H., Diallo J.S., Le Page C., Lessard L., Filali-Mouhim A., Begin L.R., Mes-Masson A.M., and Saad F. Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int. 100 (2007) 303
15. Koumakpayi I.H., Diallo J.S., Le Page C., Lessard L., Gleave M., Begin L.R., Mes-Masson A.M., and Saad F. Expression and nuclear localization of ErbB3 in prostate cancer. Clin. Cancer Res. 12 (2006) 2730
16. Le Page C., Koumakpayi I.H., Alam-Fahmy M., Mes-Masson A.M., and Saad F. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br. J. Cancer 94 (2006) 1906
17. Lessard L., Mes-Masson A.M., Lamarre L., Wall L., Lattouf J.B., and Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int. 91 (2003) 417
18. McArdle P.A., Canna K., McMillan D.C., McNicol A.M., Campbell R., and Underwood M.A. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J. Cancer 91 (2004) 541
19. Mercader M., Bodner B.K., Moser M.T., Kwon P.S., Park E.S., Manecke R.G., Ellis T.M., Wojcik E.M., Yang D., Flanigan R.C., Waters W.B., Kast W.M., and Kwon E.D. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14565
20. Mercader M., Sengupta S., Bodner B.K., Manecke R.G., Cosar E.F., Moser M.T., Ballman K.V., Wojcik E.M., and Kwon E.D. Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int. 99 (2007) 60
21. Miller A.M., Lundberg K., Ozenci V., Banham A.H., Hellstrom M., Egevad L., and Pisa P. CD4 + CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177 (2006) 7398
22. Miller A.M., and Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol. Immunother. 56 (2007) 81
23. Montironi R., and Schulman C.C. Pathological changes in prostate lesions after androgen manipulation. J. Clin. Pathol. 51 (1998) 5
24. Morgan M.E., van Bilsen J.H., Bakker A.M., Heemskerk B., Schilham M.W., Hartgers F.C., Elferink B.G., van der Zanden L., de Vries R.R., Huizinga T.W., Ottenhoff T.H., and Toes R.E. Expression of FOXP3 mRNA is not confined to CD4 + CD25+ T regulatory cells in humans. Hum. Immunol. 66 (2005) 13
25. Oefelein M.G., Ricchiuti V.S., Conrad P.W., Goldman H., Bodner D., Resnick M.I., and Seftel A. Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology 60 (2002) 120
26. Ohlson N., Wikstrom P., Stattin P., and Bergh A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 62 (2005) 307
27. Olsen N.J., Watson M.B., Henderson G.S., and Kovacs W.J. Androgen deprivation induces phenotypic and functional changes in the thymus of adult male mice. Endocrinology 129 (1991) 2471
28. Richardsen E., Uglehus R.D., Due J., Busch C., and Busund L.T. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology 53 (2008) 30
29. Sari A., Serel T.A., Candir O., Ozturk A., and Kosar A. Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma. BJU Int. 84 (1999) 851
30. Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., DeMarzo A.M., Meeker A.K., Isaacs W.B., and Drake C.G. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 14 (2008) 3254
31. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25 (2006) 195
32. Shimura S., Yang G., Ebara S., Wheeler T.M., Frolov A., and Thompson T.C. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 60 (2000) 5857
33. Sutherland J.S., Goldberg G.L., Hammett M.V., Uldrich A.P., Berzins S.P., Heng T.S., Blazar B.R., Millar J.L., Malin M.A., Chidgey A.P., and Boyd R.L. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 175 (2005) 2741
34. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., and Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351 (2004) 1502
35. Vesalainen S., Lipponen P., Talja M., and Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 30A (1994) 1797
36. Walker M.R., Kasprowicz D.J., Gersuk V.H., Benard A., Van Landeghen M., Buckner J.H., and Ziegler S.F. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4 + CD25- T cells. J. Clin. Invest. 112 (2003) 1437